Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 497-513

  Holmes, Jacinta A ^a   Desmond, Paul V ^a   Thompson, Alexander J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genetic testing; Hepatitis C virus infection; IL28B; Interferon ; ITPA; Peginterferon ribavirin; Predictors of treatment outcome; Ribavirin induced anemia

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ANEMIA; DEMOGRAPHY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; REVIEW; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS PATHOGENESIS;

GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES;

EID: 80051952108     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.009     Document Type: Review

References (83)

1. Sheppard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Thomas D.L., Seeff L.B. Natural history of hepatitis C. Clin Liver Dis 2005, 9:383-398. vi.
3. Yu M.L., Lin S.M., Chuang W.L., et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006, 11:985-994.
4. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
6. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomised study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
7. Jacobson I.M., Brown R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat dosed ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971-981.
8. Nakagawa M., Sakamoto N., Ueyama M., et al. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 2010, 45:656-665.
9. Shirakawa H., Mastsumoto A., Joshita S., et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-1760.
10. Murayama M., Katano Y., Nakano I., et al. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. J Med Virol 2007, 79:35-40.
11. Akuta N., Suzuki F., Hirakawa M., et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009, 81:452-458.
12. Kitamura S., Tsuge M., Hatakeyama T., et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther 2010, 15:1087-1097.
13. Okanoue T., Itoh Y., Hashimoto H., et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009, 44:952-963.
14. Toyoda H., Kumada T., Tada T., et al. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol 2010, 25:1072-1078.
15. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457.
16. Gerlach J.T., Diepolder H.M., Zachoval R., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
17. Alberti A., Boccato S., Vario A., et al. Therapy of acute hepatitis C. Hepatology 2002, 36:S195-S200.
18. Licata A., Di Bona D., Schepis F., et al. When and how to treat acute hepatitis C?. J Hepatol 2003, 39:1056-1062.
19. Wiegand J., Buggisch P., Boecher W., et al. Early monotherapy with pegylated alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43:250-256.
20. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
21. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in black and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
22. Liu C.H., Liu C.J., Lin C.L., et al. Pegylated intergeron-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicentre, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
23. Hepburn M.J., Hepburn L.M., Cantu N.S., et al. Difference in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004, 117:163-168.
24. Missiha S., Heathcote J., Arenovich T., et al. Impact of Asian race on response to combination therapy with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007, 102:2181-2188.
25. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
26. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
27. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41(10):1105-1109.
28. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
29. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C. Nature 2009, 461:798-802.
30. Fellay J., Thompson A.J., Ge D., et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010, 464:405-408.
31. Thompson A.J., Fellay J., Patel K., et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010, 139:1181-1189.
32. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. NEJM 2009, 361(6):580-593.
33. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
34. Neumann A., Bibert S., Haagmans B., et al. IL28B polymorphism is significantly correlated with IFB anti-viral effectiveness already on first day of pegylated interferon-α and ribavirin therapy of chronic HCV infection 2010, EASL, Vienna (Austria), [abstract: #2011].
35. Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011, in press.
36. Stättermayer A.F., Stauber R., Hofer H., et al. Impact of IL28B genotype on the early and sustained virological response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011, 9(4). 344.e2-350.e2.
37. Sarrazin C., Susser S., Doehring A., et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011, 54(3):415-421.
38. Kawaoka T., Hayes C.N., Ohishi W., et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011, 54(3):408-414.
39. Scherzer T.M., Hofer H., Stäettermayer A.F., et al. Early virological response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011, 54(5):866-871.
40. Moghaddam A., Melum E., Reinton N., et al. IL28B genetic variation and treatment response in patients with HCV genotype 3 infection. Hepatology 2011, 53(3):746-754.
41. Yu M.L., Huang C.F., Huang J.F., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus in genotype 2 infection in Asian patients. Hepatology 2011, 53(1):7-13.
42. Mangia A., Thompson A.J., Santoro R., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virological response. Gastroenterology 2010, 139:821-827.
43. Montes-Cano A.M., García-Lozano J.R., Abad-Molina C., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
44. Rallón N.I., Naggie S., Benito J.M., et al. Association of a single nucleotide polymorphisms near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29.
45. De Araújo E.S., Dahari H., Cotler S.J., et al. Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV coinfected patients. J Acquir Immune Defic Syndr 2011, 56(2):95-99.
46. Pineda J.A., Caruz A., Rivero A., et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010, 51:788-795.
47. Aparicio E., Parera M., Franco S., et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010, 5:e13771.
48. Yilmaz N., Shiffman M.L., Stravitz R.T., et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007, 13:975-983.
49. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673-684.
50. Brown R.S. Hepatitis C and liver transplantation. Nature 2005, 436:973-978.
51. Chalasani N., Manzarbeitia C., Ferenci P., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289-298.
52. Fernández I., Meneu J.C., Colina F., et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006, 12:1805-1812.
53. Mukherjee S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2005, 37:4403-4405.
54. Fukuhara T., Taketomi A., Motomura T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139:1577-1585.
55. Charlton M.R., Thompson A.J., Veldt B.J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53:317-324.
56. Lange C.M., Moradpour D., Doehring A., et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C liver graft reinfection. J Hepatol 2010, [Epub ahead of press].
57. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for treatment of chronic hepatitis C genotype 1 nonresponders. N Engl J Med 2011, 54:1207-1217.
58. Poordad F., McCone J., Bacon B.R., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. N Engl J Med 2011, 54:1195-1206.
59. Jacobson I.A., McHutchison J.G., Dusheiko G.M., et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 Advance study 2010, AASLD, Boston (MA), [abstract: 211].
60. Akuta N., Suzuki F., Hirakawa M., et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52:421-429.
61. Fried M.W., Buti M., Dore G.J., et al. Efficacy and safety of TMC435 in combination with peginterferon alpha-2a plus ribavirin in treatment naive genotype 1 HCV patients: 24 week-interim results from the PILLAR study. Hepatology 2010, 52(SUPPL 1):LB5. [abstract form].
62. Tillmann H.L., Thompson A.J., Patel K., et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139:1586-1592.
63. Grebely J., Petoumenos K., Hellard M., et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52:1216-1224.
64. Kotenko S.V., Gallagher G., Baurin V.V., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:66-77.
65. Sheppard P., Kindsvogel W., Xu W., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
66. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-3854.
67. Muir A.J., Shiffman M.L., Zaman A., et al. Phase 1b study of pegylated interferon lambda-1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832.
68. Honda M., Sakai A., Yamashita T., et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for CHC. Gastroenterology 2010, 139:499-509.
69. Urban T., Thompson A.J., Bradrick S.S., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896.
70. Shebl F.M., Maeder D., Shao U., et al. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 2010, 139:1422-1424.
71. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
72. Bain V.G., Lee S.S., Peltekian K., et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. Aliment Pharmacol Ther 2008, 28:43-50.
73. Hiramatsu N., Oze T., Yakushijin T., et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009, 16:586-594.
74. Reddy K.R., Shiffman M.L., Morgan T.R., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
75. Akuta N., Suzuki F., Yawamura Y., et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007, 46:403-410.
76. Bierau J., Lindhout M., Bakker J.A. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenetics 2007, 8:1221-1228.
77. Stocco G., Choek M.H., Crews K.R., et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphocytic leukemia. Clin Pharmacol Ther 2009, 85:164-172.
78. Thompson A.J., Santoro R.S., Piazzolla V., et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011, 53:389-395.
79. Hitomi Y., Cirulli E.T., Fellay J., et al. Inosine triphosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function. Gastroenterology 2011, 140(4):1314-1321.
80. Kurosaki M., Matsunaga K., Hirayama I., et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010, 40:251-260.
81. Veldta B.J., Poteruchaa J.J., Watta D.S., et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008, 8:2426-2433.
82. Corey K.E., Mendez-Navarro J., Gorospe E.C., et al. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010, 17:201-207.
83. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology 2010, 52:2243.